Metrics as of 10/15/2026, 04:48 PM (Berlin time), refresh in progress.
C4 Therapeutics Stock
C4 Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Andrew J. Hirsch
- Employees
- 104
- Market cap
- $340 M
- IPO
- 02/10/2020
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutic candidates. Its core strategy involves degrading proteins implicated in disease, addressing a range of conditions including cancer, neurodegenerative disorders, and other illnesses. The…
C4 Therapeutics stock: price history
1D
-0.4%
1W
-12.3%
1M
-19.7%
6M
-5.1%
YTD
+45.0%
1Y
+11.7%
2Y
-60.4%
5Y
-93.7%
10Y
–
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~3% weaker price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 13/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about C4 Therapeutics
Analyst assessment of C4 Therapeutics
PRICE TARGET LOW
US$6.00
CONSENSUS
US$11.33
MEDIAN
US$10.00
PRICE TARGET HIGH
US$20.00
0
STRONG BUY
10
BUY
3
HOLD
1
SELL
0
STRONG SELL
14
TOTAL · Buy
As of: 01/06/2026
C4 Therapeutics stock metrics
P/E
-2.65
P/B
1.4
EV/EBITDA
-3.05
RETURN ON EQUITY
-9.6%
NET MARGIN
-355.9%
DEBT/EQUITY
0.23
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
76.8%
FLOAT SHARES
94,501,758
AVG. DAILY VOLUME (30D)
2,251,895
Insider transactions (SEC)
Anderson Kenneth Carl
GROGAN DONNA ROY
Adams Kendra
Adams Kendra
REYNO LEONARD
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -0.4%
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about C4 Therapeutics stock
What does C4 Therapeutics do?
C4 Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Andrew J. Hirsch, the company employs around 104 people.
The IPO was on 02/10/2020; the stock trades on NASDAQ under the ticker CCCC.
What do analysts say about C4 Therapeutics stock?
14 analysts rate the stock, the consensus is Buy (as of 01/06/2026).
The average price target is US$11.33, ranging from US$6.00 to US$20.00, with a median of US$10.00.
This is an external assessment, not a statement by Market Jury.
When does C4 Therapeutics report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly -3% stronger than usual.
Does C4 Therapeutics pay a dividend?
No, C4 Therapeutics currently does not pay a dividend.
Which stocks are comparable to C4 Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get C4 Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess C4 Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.